The Screening Unit offers image-based screening with automated microscopes in 384-well format and automated identification and quantification of up to 6 differently fluorescently labeled cellular structures. FVB-FMP can use primary cells from mice or patients and have also experience in usage of iPS cells.
The Screening Unit of the FVB-FMP offers a broad portfolio of screening technologies to identify drugs or proteins (RNAi-interference, CRISPR/Cas9) involved in development of healthy or disease determined biological systems. More then 300 projects from Europe and abroad have been supported in the past. This knowledge is passed to the supported projects without any loss of IP to your project and generated results. We work with cells from patients, animal derived primary cells and organisms like C. elegans or Zebrafish embryos. For support in 384-well or other format microtiter plates we need an assay already established in your lab and help to downscale it towards lowest volumes to reduce your costs for reagents towards a minimum. We already use three ArrayScan microscopes (one embedded in a FreedomEvo Workstation and providing a climate chamber for live cell assays) and one FLIPR-Tetra system for kinetic imaging. We already organized security settings to be able to analyze human cells from hospitals. Our detection systems support all kinds of read outs with the only exception being the usage of radioactively-labeled probes. We support image-based screens providing fluorescent or luminescent readouts, but also bright-field imaging and readouts based on changes in morphology of cells or cell-groups in colonies.
100,000 (full commercial set) of the EU-OPENSCREEN ERIC compound library
We are using KNIME and the software provided by the vendors of microscopes for automated object identificalion and quantification of fluorescent or luminescent detection/quantification of cellular response
Please note that this project includes the possibility of re-screening during potential chemical optimization under the medicinal chemistry call starting in 2021 (tentative date).
The applicants needs an assay demonstrating a good signal to noise ratio in your labscale assay, which we will downscale to 20-40 µL volumes in 384well microtiter plates for HTS. Your test needs to pass an assay acceptance test (i.e., half plate negative and the other part positive cellular responses) to validate robustness and not a random instability independent from the target for interference. If your assay demonstrates an appropriate z-prime factor you will be able to start HTS.
As specifics of the assay transfer procedure may vary between partner sites, the applicant and the individual sites will agree on the appropriate steps and logistics together.
Cell-based assays using complex cellular systems
drug discovery, small molecules, high-throughput screening, cell-based assays
June-01-2019 (20:00 CET)
September-30-2019 (20:00 CET)
Scientific contact: Jens Peter von Kries, email@example.com
Technical contact: Martin Neuenschwander, firstname.lastname@example.org
Machine/Methods contact: Andreas Oder, email@example.com; Carola Seyffarth, firstname.lastname@example.org
Leibniz Research Institute for Molecular Pharmacology in the Forschungsverbund Berlin e.V.